View Older Stories View More Recent Stories
-
Stifel Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Raymond James Reiterates Market Perform Rating on Medtronic, Inc. (MDT)
-
Medtronic (MDT) Tops Q3 EPS by 3c; offers guidance
-
Medtronic set to deliver steady growth as FX pressures ease and pipeline gains traction
-
Medtronic (MDT) call put ratio 3.7 calls to 1 put with a focus on March 95 calls into quarter results
-
Medtronic (MDT) call put ratio 1.2 calls to 1 put into quarter results
-
Inogen (INGN) Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West
-
Medtronic (MDT) appoints Thierry Piéton as CFO
-
Citi Reiterates Neutral Rating on Medtronic, Inc. (MDT)
-
Medtronic (MDT) announces CMS national coverage analysis for Symplicity Spyral Renal Denervation System
-
RBC's Best Picks For 2025 in Medical Supplies & Devices: 'Oasis of Opportunity Awaits as MedTech Momentum Continues'
-
Medtronic, Inc. (MDT) PT Raised to $100 at Mizuho
-
Medtronic (MDT) Declares $0.70 Quarterly Dividend; 3.3% Yield
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Medtronic, Inc. (MDT) PT Raised to $109 at Barclays
-
Medtronic (MDT) receives FDA clearance for new InPen app
-
TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Lowered to $93 at Baird
-
Medtronic, Inc. (MDT) PT Raised to $93 at UBS
-
Needham Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Medtronic (MDT) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY25 EPS Guidance
-
Medtronic (MDT) call put ratio 2.9 calls to 1 put with a focus on November 22 weekly 89 calls into quarter results
-
Medtronic (MDT) November weekly 87 straddle priced into quarter results
-
Medtronic (MDT) Gains, Boston Scientific (BSX) Declines
-
Medtronic (MDT) receives FDA approval of Affera Mapping and Ablation System and Sphere-9™ Catheter
-
Medtronic, Inc. (MDT) PT Raised to $96 at Baird
-
RBC Capital Upgrades Medtronic, Inc. (MDT) to Outperform
-
Medtronic (MDT) short duration October 11 weekly 89 calls active
-
Medtronic (MDT) issues voluntary recall notifying insulin pump users of potential risks of shortened pump battery life
-
TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Piper Sandler Reiterates Neutral Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Raised to $90 at Truist Securities
-
Medtronic (MDT) Receives FDA Approval of Expanded MRI Labeling for Medtronic Percept PC and Percept RC, as Well as Medtronic Activa PC, RC and SC
-
Selloff in MedTech stocks 'seems overdone': Citi
-
Piper Sandler Reiterates Overweight Rating on Medtronic, Inc. (MDT)
-
Goldman Sachs Reiterates Sell Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Raised to $94 at Oppenheimer
-
Medtronic, Inc. (MDT) PT Raised to $98 at Mizuho
-
Medtronic, Inc. (MDT) PT Raised to $90 at Baird
-
Medtronic, Inc. (MDT) PT Raised to $106 at Wells Fargo
-
Wolfe Research Reiterates Underperform Rating on Medtronic, Inc. (MDT)
-
Deutsche Bank Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Medtronic, Inc. (MDT) PT Raised to $87 at Stifel
-
Needham Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Midday movers: Lilly, Palo Alto and Fabrinet rise; Lowe's, Boeing fall
-
TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
Medtronic hikes fiscal 2025 guidance as Q1 earnings beat expectations
-
Medtronic (MDT) Tops Q1 EPS by 3c, Offers FY25 EPS Guidance
-
Medtronic (MDT) call put ratio 2.5 calls to 1 put into quarter results
-
Barclays Reiterates Overweight Rating on Medtronic, Inc. (MDT)
